Form SC 13D - General Statement of Acquisition of Beneficial Ownership:
SEC Accession No. 0000921895-22-001894
Filing Date
2022-06-03
Accepted
2022-06-03 15:59:15
Documents
1

Document Format Files

Seq Description Document Type Size
1 sc13d13398002_06032022.htm SC 13D 61125
  Complete submission text file 0000921895-22-001894.txt   62519
Mailing Address 1201 NORTH MARKET STREET SUITE 111 WILMINGTON DE 19801
Business Address
Javitt Jonathan C (Filed by) CIK: 0001303782 (see all company filings)

Type: SC 13D

Mailing Address 1201 N. MARKET STREET SUITE 111 WILMINGTON DE 19801
Business Address 1201 N. MARKET STREET SUITE 111 WILMINGTON DE 19801 484-254-6134
NRX Pharmaceuticals, Inc. (Subject) CIK: 0001719406 (see all company filings)

EIN.: 822844431 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D | Act: 34 | File No.: 005-90195 | Film No.: 22994200
SIC: 2834 Pharmaceutical Preparations